Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00099255 · ClinicalTrials.gov registry record · Phase 2

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

A Phase 2 study of Large-cell Lymphoma, sponsored by Seagen.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
13
Study locations

NCT00099255 is a Phase 2 study of Large-cell Lymphoma that has completed, run by Seagen. The registered enrollment target is 40 participants, below the 88-participant average among 4 other Large-cell Lymphoma trials with a reported enrollment target (55% lower). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00099255, a Phase 2 study of Large-cell Lymphoma, has completed, sponsored by Seagen.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
13
Study locations

Study Summary

This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.

Conditions Studied

Large-cell Lymphoma

Interventions

  • DRUG SGN-30

Study Locations (13)

California

  • University of California at Los Angeles - Los Angeles
  • Stanford University - Stanford

Illinois

  • Northwestern Universtiy - Chicago
  • University of Illinois at Chicago - Chicago

Alabama

  • University of Alabama at Birmingham - Birmingham

Connecticut

  • Yale - New Haven

Maryland

  • Johns Hopkins - Baltimore

Minnesota

  • University of Minnesota - Minneapolis

New York

  • Memorial Sloan-Kettering - New York

Ohio

  • Cleveland University - Cleveland

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2004-09
Est. Completion 2007-02
Phase Phase 2

Sponsor

Seagen

84 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00099255

The ClinicalTrials.gov registry entry for NCT00099255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 4 other Large-cell Lymphoma trials with a reported enrollment target (55% lower). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Large-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SGN-30 is the first listed.

NCT00099255 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Alabama.

Frequently Asked Questions

What is clinical trial NCT00099255 about?

NCT00099255 is a clinical study titled "Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma". This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.

What is the current status of trial NCT00099255?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-09. Estimated completion is 2007-02.

What conditions does trial NCT00099255 study?

This clinical trial studies the following conditions: Large-cell Lymphoma.

What interventions are being tested in trial NCT00099255?

The interventions under investigation include: SGN-30 (DRUG).

Who is sponsoring clinical trial NCT00099255?

This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00099255 being conducted?

This trial has 13 study locations across Alabama, California, Connecticut, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Large-cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Large-cell Lymphoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.